Skip to main content

Ionis Pharmaceuticals, Inc. (IONS) Stock

Ionis Pharmaceuticals, Inc. Stock Details, Movements and Public Alerts

Stock Details

Ionis Pharmaceuticals, Inc. (IONS), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $47.75. Over the past 52 weeks, it has ranged between $50.01 and $86.74. This places the current price at 55.0% of its 52-week high and -4.5% above its 52-week low. Recent trading volume was recorded at 61. The 14-day Relative Strength Index (RSI) stands at 24.13, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $57.96 by 17.62%. Similarly, it is below its 200-day moving average of $72.74 by 34.36%. The MACD histogram is -1.19, indicating bearish momentum (MACD Line: -2.02, Signal Line: -0.84).

52-Week Range

$86.74 - $50.01

-44.95% from high · +-4.52% from low

Avg Daily Volume

3,218,642

20-day average

100-day avg: 2,754,460

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-46.25

PEG Ratio

27.33

Potentially overvalued

Price to Book

19.37

EV/EBITDA

-14.90

EPS (TTM)

-$3.48

Price to Sales

9.78

Beta

0.42

Less volatile than market

Q:How is IONS valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is IONS's risk profile compared to the market?
With a beta of 0.42, Ionis Pharmaceuticals, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 19.37 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-64.66%

Operating Margin

-38.18%

EBITDA

$-579,484,992

Return on Equity

-105.50%

Return on Assets

-12.43%

Revenue Growth (YoY)

-40.70%

Q:How profitable and efficient is IONS's business model?
Ionis Pharmaceuticals, Inc. achieves a profit margin of -64.66%, meaning it retains $-64.66 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -38.18% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -105.50% and ROA at -12.43%, the company achieves moderate returns on invested capital.
Q:What are IONS's recent growth trends?
Ionis Pharmaceuticals, Inc.'s revenue declined by 40.70% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$8.5B

Revenue (TTM)

$874.09M

Revenue/Share (TTM)

$5.36

Shares Outstanding

166.18M

Book Value/Share

$2.66

Asset Type

EQUITY

Q:What is IONS's market capitalization and position?
Ionis Pharmaceuticals, Inc. has a market capitalization of $8.5B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 166.18M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does IONS's price compare to its book value?
Ionis Pharmaceuticals, Inc.'s book value per share is $2.66, while the current stock price is $47.75, resulting in a price-to-book (P/B) ratio of 17.98. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$84.23

76.39% upside potential

Analyst Recommendations

Strong Buy

6

Buy

10

Hold

6

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for IONS?
22 analysts cover IONS with 73% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $84.23 implies 76.4% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on IONS?
Current analyst recommendations:6 Strong Buy, 10 Buy, 6 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 15, 2026, 02:22 AM

Technical Indicators

RSI (14-day)

24.13

Oversold

50-Day Moving Average

$57.96

-17.62% below MA-50

200-Day Moving Average

$72.74

-34.36% below MA-200

MACD Line

-2.02

MACD Signal

-0.84

MACD Histogram

-1.19

Bearish

Q:What does IONS's RSI value tell investors?
The RSI (Relative Strength Index) for IONS is currently 24.13, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret IONS's MACD and moving average crossovers?
MACD analysis shows the MACD line at -2.02 below the signal line at -0.84, with histogram at -1.19. This bearish crossover indicates downward pressure. The wide histogram confirms strong momentum. The 50-day MA ($57.96) is below the 200-day MA ($72.74), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Sep 16, 2026, 01:07 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for IONS and get notified when the price changes.

Stay Ahead of the Market with Ionis Pharmaceuticals, Inc. Alerts

Set up price alerts for Ionis Pharmaceuticals, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.